BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

ADRs added ~2% in the premarket on Monday after the German vaccine maker exceeded Street forecasts with its Q2 2025 ...

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89) per share ...

BNTX will also make additional performance-based contingent payments of up to $150 million upon the achievement of certain milestones. Also, more than 300 employees of Biotheus will join BioNTech ...

BioNTech SE (NASDAQ: BNTX) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer ...